5:28 PM
 | 
Sep 13, 2012
 |  BC Extra  |  Top Story

4SC reports OS data for resminostat

4SC AG (Xetra:VSC) reported additional data from the Phase II SHELTER trial showing that second-line treatment with resminostat plus Nexavar sorafenib led to a median overall survival of 8 months in patients with hepatocellular carcinoma refractory to Nexavar. 4SC believes the 8 month median OS...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >